X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REN001 (mavodelpar) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of primary mitochondrial myopathies (PMM).
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: vTv Therapeutics
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPAR delta agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
The net proceeds will be used to fund the development of company's lead product, REN001 (mavodelpar), a potent and selective agonist of the peroxisome proliferator-activated receptor delta, in adult patients with PMM due to mitochondrial DNA, or mtDNA, defects.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases : primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
REN001 is a potent and selective PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
REN001 is a potent and selective PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
REN001 is an oral selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs.
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
